［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:Globocanestimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］SI W,SHEN J,ZHENG H,et al.The role and mechanisms of action of microRNAs in cancer drug resistance［J］.Clin Epigenetics,2019,11(1):25.
［3］MANI SA,GUO W,LIAO MJ,et al.The epithelial-mesenchymal transition generates cells with properties of stem cells［J］.Cell,2008,133(4):704-715.
［4］MITTAL V.Epithelial mesenchymal transition in tumor metastasis［J］.Annu Rev Pathol,2018,13:395-412.
［5］DONGRE A,WEINBERG RA.New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer［J］.Nat Rev Mol CellBiol,2019,20(2):69-84.
［6］ZHANG N,NG AS,CAI S,et al.Novel therapeutic strategies:Targeting epithelial-mesenchymal transition in colorectal cancer［J］.Lancet Oncol,2021,22(8):e358-e368.
［7］ZHOU P,LI B,LIU F.The epithelial to mesenchymal transition(EMT) and cancer stem cells:Implication for treatment resistance in pancreatic cancer［J］.Mol Cancer,2017,16(1):52.
［8］GUAN X,GU S,YUAN M,et al.MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition.［J］.Oncol Lett,2019,18(6):5986-5994.
［9］DENG J,BAI X,FENG X,et al.Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression［J］.Bmc Cancer,2019,19(1):618.
［10］TULCHINSKY E,DEMIDOV O,KRIAJEVSKA M,et al.EMT:A mechanism for escape from EGFR-targeted therapy in lung cancer［J］.Biochim Biophys Acta Rev Cancer,2019,1871(1):29-39.
［11］XIAO Y,XIE Q,QIN Q,et al.Upregulation of SOX11 enhances tamoxifen resistance and promotes epithelial-to-mesenchymal transition via slug in MCF-7 breast cancer cells［J］.J Cell Physiol,2020,235(10):7295-7308.
［12］DU F,LIU H,LU Y,et al.Epithelial-to-mesenchymal transition:Liaison between cancer metastasis and drug resistance［J］Crit Rev Oncog,2017,22(3-4):275-282.
［13］MA J,ZENG S,ZHANG Y,et al.BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma［J］.Cancer Lett,2017,411:117-129.
［14］CELIA-TERRASSA T,JOLLY MK.Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis［J］.Cold Spring Harb Perspect Med,2020,10(7):a036905.
［15］DZOBO K,SENTHEBANE DA,GANZ C,et al.Advances in therapeutic targeting of cancer stem cells within the tumor microenvironment:An updated review［J］.Cells,2020,9(8):1896.
［16］KAWAI T,YASUCHIKA K,ISHII T,et al.Keratin 19,a cancer stem cell marker inhuman hepatocellular carcinoma［J］.Clin Cancer Res,2015,21(13):3081-3091.
［17］CHEN J,JIN R,ZHAO J,et al.Potential molecular,cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma［J］.Cancer Lett,2015,367:1-11.
［18］MARIN JJG,MACIAS RIR,MONTE MJ,et al.Molecular bases of drug resistance in hepatocellular carcinoma［J］.Cancers(Basel),2020,12(6):1663.
［19］UNGERLEIDER N,HAN C,ZHANG J,et al.TGF-β signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells［J］.Mol Carcinogenesis,2017,56:1302-1311.
［20］DEBNATH P,HUIREM RS,DUTTA P,et al.Epithelial-mesenchymal transition and its transcription factors［J］.Biosci Rep,2022,42(1):BSR20211754.
［21］ZHANG Y,WU W,SUN Q,et al.LincROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating Twist1 mediated epithelial mesenchymal transition［J］.Mol Med Rep,2021,23(5):340.
［22］HU B,CHENG JW,HU JW,et al.KPNA3 confers sorafenib resistance to advanced hepa-tocellular carcinoma via Twist regulated epithelial-mesenchymal transition［J］.J Cancer,2019,10(17):3914-3925.
［23］SREEKUMAR R,AL-SAIHATI H,EMADUDDIN M,et al.The ZEB2-dependent emttranscriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer［J］.Mol Oncol,2021,15(8):2065-2083.
［24］YANG J,CUI R,LIU Y.MicroRNA-212-3p inhibits paclitaxel resistance through regulating epithelial-mesenchymal transition,migration and invasion by targeting zeb2 in human hepatocellular carcinoma［J］.Oncol Lett,2020,20(4):23.
［25］WANG JC,ZHANG N,HAN Q,et al.Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to regorafenib via the Gli1/Snail/E-cadherin pathway［J］.Cancer Lett,2019,444:82-93.
［26］XU S,ZHOU Y,BIEKEMITOUFU H,et al.Expression of twist,slug and snail in esophageal squamous cell carcinoma and their prognostic significance［J］.Oncol Lett,2021,21(3):184.
［27］ZHAO XY,LI L,WANG XB,et al.Inhibition of snail family transcriptional repressor 2(snai2) enhances multidrug resistance of hepatocellular carcinoma cells［J］.PLoS One,2016,11(10):e0164752.
［28］TUTUSAUS A,STEFANOVIC M,BOIX L,et al.Antiapoptotic Bcl2 proteins determine sorafenib/regorafenib resistance and Bh3-mimetic efficacy in hepatocellular carcinoma［J］.Oncotarget,2018,9:16701-16717.
［29］SHRESTHA R,PRITHVIRAJ P,BRIDLE KR,et al.Combined inhibition of TGF-β1-induced emtand PD-L1 silencing resensitizes hepatocellular carcinoma to sorafenib treatment［J］.J Clin Med,2021,10(9):1889.
［30］DENG G,CHEN Y,GUO C,et al.BMP4 promotes the metastasis of gastric cancer by inducing epithelial-mesenchymal transition via ID1［J］.J Cell Sci,2020,133(11):jcs237222.
［31］CHEN W,YANG J,ZHANG Y,et al.Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma［J］.Febs Open Bio,2019,9(2):335-347.
［32］LI Y,CHEN G,HAN Z,et al.IL-6/STAT3 signaling contributes to sorafenib resistance in hepatocellular carcinoma through targeting cancer stem cells［J］.Onco TargEts Ther,2020,13:9721-9730.
［33］周竞,吴焕淦,施茵.TNF-α/NF-κB/Snail介导上皮间质转化的作用［J］.世界华人消化杂志,2018,26(7):441-448.
ZHOU J,WU HG,SHI Y.The role of TNF-α/NF-κB/Snail in mediating epithelial-mesenchymal transition［J］.World Chinese Journal of Digestion,2018,26(7):441-448.
［34］TAN W,LUO X,LI W,et al.TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma［J］.Ebiomedicine,2019,40:446-456.
［35］DONG J,ZHAI B,SUN W,et al.Activation of phosphatidylinositol 3-kinase/AKT/Snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells［J］.PLoS One,2017,12(9):e0185088.
［36］DING J,ZHOU XT,ZOU HY,et al.Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter［J］.Lab Invest,2017,97(7):819-832.
［37］ZHOU XT,DING J,LI HY,et al.Hedgehog signalling mediates drug resistance through targeting tap1 in hepatocellular carcinoma［J］.J Cell Mol Med,2020,24(7):4298-4311.
［38］TRICOLI L,NITURE S,CHIMEH U,et al.Role of microRNAs in the development of hepatocellular carcinoma and acquired drug resistance［J］.Front Biosci,2019,24(3):545-554.
［39］FU X,LIU M,QU S,et al.Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway［J］.J Exp Clin Cancer Res,2018,37:52.
［40］JIN Y,WANG J,HAN J,et al.MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting snail1 and snail2 and suppressing wnt/β-cadherin signaling pathway［J］.Exp Cell Res,2017,360(2):210-217.
［41］JU BL,CHEN YB,ZHANG WY,et al.MiR-145 regulates chemoresistance in hepatocellular carcinoma via epithelial mesenchymal transition［J］.Cell Mol Biol,2015,61(3):12-16.
［42］YANG J,CUI R,LIU Y.MicroRNA-212-3p inhibits paclitaxel resistance through regulating epithelial-mesenchymal transition,migration and invasion by targeting zeb2 in human hepatocellular carcinoma［J］.Oncol Lett,2020,20(4):23.
［43］ZHANG Y,WU W,SUN Q,et al.LincROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating twist1 mediated epithelial mesenchymal transition［J］.Mol Med Rep,2021,23(5):340.
［44］TANG X,ZHANG W,YE Y,et al.LncRNA HOTAIR contributes to sorafenib resistance through suppressing miR-217 in hepatic carcinoma［J］.Biomed Res Int,2020,2020:9515071.
［45］ROBERTS CM,SHAHIN SA,WEN W,et al.Nanoparticle delivery of siRNA against twistto reduce drug resistance and tumor growth in ovarian cancer models［J］.Nanomedicine,2017,13:965-976.
［46］HUANG Y,ZHOU B,LUO H,et al.ZnAs@SiO2 nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling［J］.Theranostics,2019,9(15):4391-4408.
［47］LIU YM,LI XF,LIU H,et al.Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition,stemness and migratory ability of liver cancer stem cells［J］.Oncol Rep,2015,34:2977-2986.
［48］JAYACHANDRAN A,DHUNGEL B,STEEL JC.Epithelial-to-mesenchymal plasticity of cancer stem cells:Therapeutic targets in hepatocellular carcinoma［J］.J Hematol Oncol,2016,9(1):74.
［49］KELLEY RK,GANE E,ASSENAT E,et al.A phase 2 study of galunisertib(TGF-β1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma［J］.Clin Transl Gastroenterol,2019,10(7):e00056.
［50］ZENG X,YUAN Y,WANG T,et al.Targeted imaging and induction of apoptosis of drug-resistant hepatomacells by miR-122-loaded grapheneinp nanocompounds［J］.J Nanobiotechnology,2017,15(1):9.
［51］BEG MS,BRENNER AJ,SACHDEV J,et al.Phase I study of MRX34,a liposomal miR-34a mimic,administered twice weekly in patients with advanced solid tumors［J］.Invest New Drugs,2017,35(2):180-188.
［52］ZHANG Y,WEINBERG RA.Epithelial-to-mesenchymal transition in cancer:Complexity and opportunities［J］.Front Med,2018,12(4):361-373.